Evidence indicates that targeting SREBP1 can improve cancer cells' sensitivity to various anti-cancer agents, and combination therapy, such as SREBP1-related inhibitors and chemotherapeutic agents, can enhance the sensitivity to chemotherapy and radiotherapy drugs to inhibit tumor proliferation and metastasis. Here, SREBF1 is linked to cancer.